Wed 6/3/2020 05:28 ET
S&P 5003080.8225.260.82%BANKS345.741.940.56%OIL35.341.634.61%BITCOIN9530.125.720.06%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Javelin Pharmaceuticals - JAV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add JAV
From: alacirb (Rep: 6)Date: 12/16/2009 15:39
Forum: Javelin Pharmaceuticals - Msg #59Thread #672855867 (Rec: 0)

Javelin Pharmaceuticals Inc. on Wednesday submitted for review its drug target for pain management to the U.S. Food and Drug Administration.
The Cambridge, Mass.-based biotechnology company’s product, Dyloject, is a non-steroidal, anti-inflammatory drug target for the management of pain in adults.

“Our NDA (new drug application) submission for Dyloject is a significant milestone for Javelin. It reflects our commitment to patients suffering from acute moderate-to-severe pain, whose need ... in both the inpatient and day surgery settings is currently underserved,” stated Martin J. Driscoll, CEO of Javelin Pharmaceuticals Inc., in a prepared statement.

Javelin’s submission includes 16 clinical studies including two phase 3 studies involving more than 1,300 U.S. patients. Patient populations included the elderly (65 years of age and older) and patients with mild-to-moderate renal or mild hepatic insufficiency.

Diclofenac sodium, the active pharmaceutical ingredient in Dyloject is one of the most widely prescribed non-steroidal, inti inflammatory drug. It is approved and marketed in a variety of forms in the United States including several oral formulations, a topical gel as well as patch and ophthalmic drops. However, an injectable formulation is not yet available in the United States.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser alacirb: Reward | Watch | IgnoreJAV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add JAV | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.